SCHEMBL1551074

SCHEMBL1551074

CCOC(=O)COc1ccc(C#Cc2cccc(O)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 5/20 0.69
▸ GAA P10253 2/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ HPGD P15428 2/20 0.51
▸ HSD17B10 Q99714 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ PTPN1 P18031 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550806 0.88 FFAR1 (0.73) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL1550947 0.86 FFAR1 (0.66) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL1550341 0.86 GAA (0.59) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL1551412 0.82 FFAR1 (1.00) FFAR1MAPTPPARGALDH1A1CA12
SCHEMBL1550768 0.82 GAA (0.60) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL12646482 0.81 KDM4E (0.57) GAANPSR1HPGDHSD17B10KDM4E
SCHEMBL434786 0.78 GAA (0.68) GAANPSR1HPGDHSD17B10KDM4E
SCHEMBL1551617 0.78 GAA (0.56) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL1550405 0.77 FFAR1 (0.73) FFAR1GAANPSR1HPGDHSD17B10
SCHEMBL9863137 0.75 PPARA (0.67) GAANPSR1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 — — US disclosed
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 — — US disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 — — EP disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 — — EP disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 — — US disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 — — US disclosed
EP-2313360-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2011-04-27 — — EP disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 — — WO disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES GPR119, INSR, GPR65 FFAR1 6/4885GAA 663/4885NPSR1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback